Since the NFE2L2/KEAP1 mutations in cancer are often associated with poorer overall survival, a survival analysis of NSCLC patients receiving immunotherapy revealed improved clinical outcomes in comparison to other treatments, suggesting its possible beneficial use for patients with mutations in NFE2L2/KEAP1 [315]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.